Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,271
  • Shares Outstanding, K 53,869
  • Annual Sales, $ 103,780 K
  • Annual Income, $ 22,810 K
  • 60-Month Beta 0.55
  • Price/Sales 0.90
  • Price/Cash Flow 3.27
  • Price/Book 0.84
Trade SPRO with:

Options Overview Details

View History
  • Implied Volatility 238.52% ( +60.51%)
  • Historical Volatility 46.20%
  • IV Percentile 80%
  • IV Rank 31.37%
  • IV High 731.86% on 11/15/23
  • IV Low 13.00% on 10/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,585
  • Open Int (30-Day) 1,196

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.12
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +76.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6250 +5.85%
on 03/01/24
1.8900 -8.99%
on 03/14/24
+0.0600 (+3.61%)
since 02/28/24
3-Month
1.3300 +29.32%
on 02/08/24
1.8900 -8.99%
on 03/14/24
+0.2600 (+17.81%)
since 12/28/23
52-Week
0.9900 +73.74%
on 10/26/23
1.9950 -13.78%
on 05/08/23
+0.3700 (+27.41%)
since 03/28/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SPRO : 1.7200 (-1.71%)
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

BMY : 54.23 (+1.84%)
EXEL : 23.73 (-0.54%)
LGND : 73.10 (+2.57%)
SPRO : 1.7200 (-1.71%)
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

LGND : 73.10 (+2.57%)
PCRX : 29.22 (+0.62%)
BLUE : 1.2800 (-6.23%)
SPRO : 1.7200 (-1.71%)
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VRDN : 17.51 (unch)
SPRO : 1.7200 (-1.71%)
Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

PRGO : 32.19 (+2.32%)
ADAP : 1.5800 (unch)
SPRO : 1.7200 (-1.71%)
LSTA : 3.12 (-4.29%)
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

LGND : 73.10 (+2.57%)
PCRX : 29.22 (+0.62%)
SPRO : 1.7200 (-1.71%)
VTRS : 11.94 (+0.93%)
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

LGND : 73.10 (+2.57%)
FATE : 7.34 (unch)
SPRO : 1.7200 (-1.71%)
BHC : 10.61 (+1.14%)
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

ADAP : 1.5800 (unch)
SPRO : 1.7200 (-1.71%)
KRTX : 329.83 (+0.03%)
LSTA : 3.12 (-4.29%)
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

AGIO : 29.24 (+0.41%)
ADAP : 1.5800 (unch)
SPRO : 1.7200 (-1.71%)
LSTA : 3.12 (-4.29%)
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

MRK : 131.95 (+0.15%)
MRNA : 106.56 (-3.64%)
SPRO : 1.7200 (-1.71%)
LSTA : 3.12 (-4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.8200
2nd Resistance Point 1.7900
1st Resistance Point 1.7700
Last Price 1.7200
1st Support Level 1.7200
2nd Support Level 1.6900
3rd Support Level 1.6700

See More

52-Week High 1.9950
Last Price 1.7200
Fibonacci 61.8% 1.6111
Fibonacci 50% 1.4925
Fibonacci 38.2% 1.3739
52-Week Low 0.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar